



# Mepolizumab improves outcomes in patients with CRSwNP with one or more prior nasal polyp surgeries



In both subgroups by Week 52, treatment with **mepolizumab** versus **placebo** resulted in **greater improvement from baseline in NP score and symptoms**



Mepolizumab significantly reduced

- 73%** Risk of repeat surgery
- 63%** Odds of requiring ≥ 1 OCS course

Vs placebo in patients with 1 Prior surgery



- Mepolizumab improves outcomes in patients with CRSwNP with one or multiple prior surgeries
- May offer greater benefit when initiated after a single surgery

CRSwNP, chronic rhinosinusitis with nasal polyps; NP, nasal polyps; OCS, oral corticosteroids; SC, subcutaneous; SNOT, sino-nasal outcome test; VAS, visual analogue scale

This study was funded by GSK (GSK ID 205687).

Han JK, Mullol J, Wagenmann M, et al. Rhinology 2026 <https://doi.org/10.4193/Rhin25.599>